KATHMANDU : Kantipur Pharmaceuticals IPO approval received official clearance from the Securities Board of Nepal (SEBON) as the company prepares to issue ordinary shares worth Rs 80 crore. Following this regulatory endorsement, Kantipur Pharmaceuticals Lab Limited will release a total of 80 lakh unit shares into the primary capital market. Investors can track official issue pipeline reports directly on the Securities Board of Nepal platform.
Consequently, this approval advances public equity participation within Nepal’s domestic pharmaceutical manufacturing sector. Therefore, institutional and retail market participants are closely monitoring upcoming subscription dates.
Allocation Breakdown for Retail and Other Investors
According to Kantipur Pharmaceuticals IPO approval terms, the company will issue its ordinary shares at a face value of Rs 100 per share:
-
General Public Allocation: Offering 17 lakh shares (21.25 percent of total issuance) specifically for public retail investors.
-
Other Groups Allocation: Reserving 63 lakh shares (78.75 percent of total issuance) for promoters, employees, and designated investor categories.
-
Total Issue Volume: Summarizes to 80 lakh unit shares valued at Rs 800 million.
Furthermore, Muktinath Capital Limited will manage the entire sales and issue management process. To track secondary listings and trading rules, visit the official Nepal Stock Exchange portal. You can also explore our coverage on Vision Lumbini IPO issuance details.
Strategic Significance for Domestic Pharmaceutical Industry
Establishing a public capital base allows pharmaceutical labs to expand domestic production of essential human and veterinary medicines.
Additionally, expanding local manufacturing decreases national reliance on imported pharmaceutical products. Readers can examine industrial trade policies on the Ministry of Industry, Commerce and Supplies portal. For broader financial market updates, read our analysis on Nepal life insurance premium collection Q1 growth.
Primary Market Momentum in Manufacturing
Ultimately, securing SEBON authorization marks a major corporate milestone for pharmaceutical expansion in Nepal.
Thus, Kantipur Pharmaceuticals IPO approval provides fresh momentum for industrial growth within the national stock market.
Published on 2026-11-05 14:31






